APPILI THERAPEUTICS INC - APLIF STOCK NEWS

Appili Therapeutics Inc. has announced a Notice of Allowance for new patent claims for ATI-1501, a liquid oral reformulation of the antibiotic metronidazole. This patent strengthens ATI-1501's position as a convenient alternative for patients who struggle with the bitter taste of current metronidazole tablets, which are widely prescribed for parasitic and bacterial infections. Appili and partner Saptalis Pharmaceuticals expect FDA approval for ATI-1501 by the end of 2023.

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) announced a significant funding boost from the U.S. Department of Defense (DOD) for its ATI-1701 vaccine project, receiving at least US$14 million over two years. This funding, a 40% increase from prior projections, will allow the company to advance its biodefense efforts against the high-priority biothreat of Francisella tularensis. Additionally, Dr. Don Cilla has been appointed as CEO and Dr. Armand Balboni as Chair of the Board, ensuring strong leadership for this critical initiative.

Appili Therapeutics (OTCQX: APLIF) announced a strategic reprioritization, focusing on three key programs: ATI-1701, ATI-1501, and ATI-1801. The company received over US$10 million in funding from the DTRA to advance ATI-1701, aiming for FDA approval by end of 2023. During Q2, the net loss was $4 million, down from $18.5 million year-over-year, reflecting decreased R&D expenses.

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) held its annual and special meeting of shareholders, where all proposed resolutions were approved. Key outcomes include the election of directors such as Ian Mortimer and Brian Bloom, with votes for Mortimer at 98.42%. Shareholders re-appointed PricewaterhouseCoopers as the independent auditor and approved amendments to the stock option plan to a rolling 10% structure. Further details on voting results are available on the Company’s SEDAR profile.

Appili Therapeutics Inc. (TSX:APLI; OTCQX:APLIF) reported its Q1 fiscal 2023 results, ending June 30, 2022. The company recorded a net loss of $2.32 million ($0.03 loss per share), a significant decrease from $7.36 million loss in the same quarter last year. Key highlights include securing over $10 million in funding for the ATI-1701 vaccine candidate, a successful presentation at the WorldLeish7 Conference for ATI-1801, and completing equity financing of $4.5 million. Cash and short-term investments totaled $5.55 million as of June 30, 2022.

Appili Therapeutics (TSX:APLI; OTCQX:APLIF) announced participation in the WorldLeish conference from August 1-6, 2022, where executives will present updates on ATI-1801, a treatment for cutaneous leishmaniasis. The formulation has shown safety and efficacy in Phase 2 and 3 studies, addressing a serious public health concern affecting hundreds of thousands globally. The presentation is set for August 4, 2022, in Colombia. Appili aims to provide a non-invasive, outpatient solution for this neglected disease.

Appili Therapeutics (TSX: APLI; OTCQX: APLIF) has announced its financial results for the year ending March 31, 2022, reporting a net loss of $25.1 million, up $10.8 million from the previous year. The company attributed this increase primarily to heightened research and development expenses. Cash reserves dropped to $6.7 million from $16.1 million. Key developments include a US$10 million funding commitment from the U.S. Department of Defense and plans for regulatory approval of its antibiotic candidate, ATI-1501.

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) announced that Stéphane Paquette, Vice President of Corporate Development, will present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2022. The presentation will focus on updates regarding Appili's pipeline of novel anti-infectives, including the biodefense vaccine candidate ATI-1701 and the clinical program for ATI-1801, aimed at treating cutaneous leishmaniasis. The conference takes place at the Metro Toronto Convention Centre.

Appili Therapeutics (OTCQX: APLIF) announced the addition of ATI-1801, a topical treatment for cutaneous leishmaniasis, to its pipeline. This drug, already proven safe and effective in a Phase 3 study, offers an outpatient alternative to current invasive treatments. With a significant clinical cure rate (82% vs 58%; p < 0.001), ATI-1801 is set for FDA discussions later this year for a new drug application. Appili aims to secure funding and partnerships to complete development, and believes ATI-1801 may qualify for a priority review voucher, potentially enhancing its market value.